menu search

ESALY / Dow Jones Newswires: Eisai shares sink after Japan regulators seek more data for review of Alzheimer's drug

Dow Jones Newswires: Eisai shares sink after Japan regulators seek more data for review of Alzheimer's drug
Eisai Co. 4523, -8.96% shares fell as much as 9.2% early Thursday morning after a Japanese government panel sought additional data for a review of the company's Aduhelm drug for Alzheimer's. Read More
Posted: Dec 22 2021, 23:52
Author Name: Market Watch
Views: 111690

ESALY News  

Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer

By PRNewsWire
March 23, 2023

Eisai to Present Research from Oncology Portfolio at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer

Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Or more_horizontal

FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July

By CNBC
March 6, 2023

Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage

By CNBC
February 17, 2023

Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage

Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout of the treatment will take years. more_horizontal

Alzheimer's drug Leqembi: Eisai U.S. president

By Yahoo Finance
February 13, 2023

Alzheimer's drug Leqembi: Eisai U.S. president

Eisai U.S. President Ivan Cheung joins Yahoo Finance Live to discuss the latest news surrounding Alzheimer's treatment with Leqembi. more_horizontal

Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript

By Seeking Alpha
February 6, 2023

Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript

Eisai Co., Ltd. (OTCPK:ESALF) Q3 2022 Earnings Conference Call February 6, 2023 3:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice Preside more_horizontal

Eisai files for full FDA approval for Alzheimer's drug Leqembi

By Reuters
January 6, 2023

Eisai files for full FDA approval for Alzheimer's drug Leqembi

Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its more_horizontal

CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval

By CNBC Television
January 6, 2023

CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval

CNBC's Meg Tirrell talks to Ivan Cheung, Eisai U.S. CEO on the company's Alzheimer's drug receiving approval from the FDA today. With CNBC's Tyler Mat more_horizontal

FDA approves Biogen-Eisai Alzheimer's drug, China in talks to make Pfizer Paxlovid generic

By Yahoo Finance
January 6, 2023

FDA approves Biogen-Eisai Alzheimer's drug, China in talks to make Pfizer Paxlovid generic

Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative Alzheimer's treatment drug and China's pla more_horizontal


Search within

Pages Search Results: